Thiazolidinediones (TZD) compounds have been developed in order to counteract the insulin resistance state observed in Type II diabetes mellitus [1] . Although TZD clearly enhance the peripheral sensitivity to insulin in human and animal models of insulin resistance, the precise mechanism of this effect is not known [2, 3] . The elucidation of the mechanism of the action of TZD remains a major issue for their use in the treatment of Type II diabetes mellitus.
Summary Thiazolidinediones are potent antidiabetic compounds, which act by enhancing peripheral insulin sensitivity. They are also activators of the peroxisome proliferator activated receptor g in adipose tissue. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat and hence the capacity of adipose tissue to utilize glucose. Nevertheless, muscles are the major site for insulin-mediated glucose disposal. The increase of muscle glucose utilization under thiazolidinedione treatment could be secondary to local adipose tissue differentiation. This possibility is supported by the fact that a thiazolidinedione-induced myoblast conversion into adipocytes has been described in vitro. To address this problem, we have studied the in vivo effect of a pioglitazone treatment on insulin-induced glucose utilization and the expression of genes exclusively expressed in mature adipocytes in three muscles differing by their fibre composition in Zucker (fa/fa) rats.
Whereas pioglitazone treatment increased insulinstimulated glucose utilization to the same extent in all muscle types, an adipocyte differentiation was only present in the oxidative muscle, the soleus. Soleus muscle was also the only one in which the presence of genes specific for adipose tissue could be detected before the pioglitazone treatment. There was no detectable expression of adipocyte specific genes in the extensor digitorum longus or in the epitrochlearis muscles before or after the drug treatment. We conclude that pioglitazone effects on muscle glucose metabolism cannot be due to a local adipocyte differentiation, and that the conversion of myoblasts into adipocytes under thiazolidinedione stimulation observed in vitro is, if it exists, a marginal phenomenon in vivo. [Diabetologia (1998) 
41: 963±968]
Keywords Thiazolidinedione, PPARg, muscle, Zucker fa/fa rat, adipocyte differentiation, glucose utilization. blasts or even myoblasts are able to respond in vitro to TZD by partial conversion into an adipocyte-like phenotype [9±11] .
In a recent paper, we showed that a TZD compound, pioglitazone, markedly improves the glucose tolerance in an animal model of insulin resistance, the obese Zucker fa/fa rat [12] . Pioglitazone also strongly induced adipocyte differentiation and increased adipose tissue glucose utilization at post-absorptive insulin concentrations in vivo [12] .
It is clearly established that muscles are the major site for insulin-mediated glucose disposal. Thus, this tissue must also be involved in the pioglitazone-induced increase in glucose disposal under insulin stimulation. However, since PPARg is expressed mainly in adipose tissue, we hypothesize that part of the increase of muscle glucose utilization under pioglitazone is secondary to differentiation of adipocyte precursors or even myoblasts to adipose tissue.
In the present paper, we show that both oxidative and glycolytic muscles respond equally to a pioglitazone treatment by enhancing their insulin-stimulated glucose utilization, though an adipocyte differentiation was observed in an oxidative muscle only, probably from pre-existing preadipocytes. We conclude therefore that local adipocyte differentiation is not responsible for the pioglitazone effect on muscle glucose metabolism and that the TZD-induced differentiation of myoblasts to adipocytes observed in vitro is not a major effect in in vivo experiments.
Materials and methods
Animals. Animal studies were conducted according to the French Guidelines for the Care and Use of Experimental Animals. Female obese Zucker (fa/fa) rats were bred in our laboratory from pairs originally provided by the Harriet G. Bird Memorial Laboratory (Stowe, Mass., USA). The animals were maintained under a constant light-dark cycle (light from 07.00 hours to 19.00 hours) and given free access to chow pellets and water. The rats were treated by gavage with 10 mg × kg ±1 × day ±1 of pioglitazone HCL (Lipha S. A., ChillyMazarin, France) each morning at 09.00 hours. A single daily dose was given to 12-week-old rats for 28 days. In each case, the last dose of pioglitazone was given 2 h before the various experiments.
Measurement of glucose turnover rate and muscle glucose utilization in the basal state or under insulin stimulation. Experiments were performed at 11.00 hours on rats which were deprived of food for 2 h and treated or not with pioglitazone for 28 days. Rats were anaesthetized using pentobarbital. A catheter was inserted into one of the carotid arteries for blood sampling and a tracheotomy was performed. In the groups studied in basal insulin conditions, a primed (7 mCi) continuous (0.2 mCi × min ±1 ) infusion of [3- 3 H]-glucose (DuPont-NEN, Boston, Mass., USA) was administered for 2 h. Blood (50 ml) was sampled at time 0, 10, 20, 30 and 40 min. This later time (40 min), is the time at which a steady-state for H]-glucose specific activity was reached (data not shown) and used for the determination of glucose turnover rate as described previously [13] . Then, 2-deoxy-[1- C]-glucose [14] . In rats, these three muscles contain substantially different proportions of fibre types: the soleus muscle contains 16 % fast oxidative glycolytic fibres and 84 % slow oxidative fibres, the extensor digitorum longus (EDL) consists of 59 % pale fast-twitch oxidative glycolytic fibres, 38 % fast glycolytic fibres and 3 % slow oxidative fibres [15, 16] ; the epitrochlearis consists of 65 % fast-twitch glycolytic fibres, 20 % fast-twitch oxidative and 15 % slow-twitch oxidative fibres [17] .
In the groups studied under insulin-stimulated conditions, a similar primed-continuous [3- 3 H]-glucose as that described above was performed. At the start of the [3- 3 H]-glucose infusion, a continuous porcine insulin (Actrapid, Novo Industry, Copenhagen, Denmark) infusion at 0.4 U × h ±1 × kg ±1 for control rats and 0.5 U × h ±1 × kg ±1 for pioglitazone-treated rats was initiated [13] . Different insulin infusion rates were used in the two groups since basal insulin concentrations are decreased twofold after the pioglitazone treatment. At 5 min time intervals, 10 ml of blood were sampled and blood glucose measured. A variable infusion of 10 % (wt/vol) glucose for control rats and 20 % (wt/ vol) for pioglitazone-treated rats was adjusted to maintain the plasma glucose concentration at their basal glycaemia. Plasma samples for insulin were collected at 0, 40, 70 and 85 min. Steady-state conditions for blood glucose, plasma H]-glucose specific activity and plasma insulin were reached within 40 min after initiation of [3- 3 H] glucose and insulin infusion (data not shown). The 2-deoxy-[1-14 C]glucose experiment was then performed as described above in order to measure muscle glucose utilization under insulin stimulation.
RNA extraction and northern blot analysis. Obese Zucker fa/fa rats were treated or not with pioglitazone during 28 days as described above. Their muscles were then sampled and immediately frozen in liquid nitrogen.
Total cellular RNAs were extracted using a guanidine thiocyanate method [18] . RNA concentrations were measured spectrophotometrically (A260). Total RNAs (15 mg) were denatured by heating at 95°C for 3 min. RNAs were size fractionated on 1 % (wt/vol) agarose gel containing 2.2 mol/l formaldehyde in 20 mmol/l 3-(N-morpholino)-propanesulfonic acid (pH 7.0), 50 mmol/l sodium acetate, and 1 mmol/l EDTA, by electrophoresis for 16±18 h at 50 V. RNA were then transferred to a nylon membrane (Hybond-N, Amersham Life Science, Bucks, UK) and were cross-linked to membranes with UV lights before hybridization. The cDNA probes were labelled by primer extension with a[ cDNA probes. The cDNA for rat fatty acid synthase (FAS), phosphoenolpyruvate carboxykinase (PEPCK) and C/EBPa were as described previously [12] . C/EBPa is a transcription factor present in adipose tissue but not in muscle [19] . The my-ogenin probe was a kind gift from Dr C. Dani (Nice, France). Each northern-blot was hybridized with a ribosomal 18S cDNA in order to verify that equivalent amounts of total RNA were loaded in each lane.
Statistical analysis. Statistical significance of differences was assessed using the Student's t-test for unpaired data.
Results
Pioglitazone improves overall insulin sensitivity in obese Zucker fa/fa rats. The treatment with pioglitazone induced a small decrease in basal blood glucose whereas basal insulin was markedly decreased (Table 1). Basal glucose turnover rate was slightly, but not significantly, increased by the pioglitazone treatment (Table 1) . During the clamp studies high and non-significantly different concentrations of plasma insulin were achieved in the two groups of rats (Table 1). Insulin-stimulated glucose turnover rate was increased twofold in the pioglitazone-treated group (Table 1) .
Glucose utilization rate in various muscles in the basal state and during the euglycaemic hyperinsulinaemic clamp. In the basal state, pioglitazone treatment increased glucose utilization only slightly in the soleus, an oxidative muscle (Fig. 1) .
A high insulin concentration increased the glucose utilization rate in the muscles of both experimental groups. However, this increase was much larger in the pioglitazone-treated group (Fig. 1) . Interestingly enough, there was no difference in the stimulation of glucose utilization among the three muscles studied. This experiment underlines the major role of muscles in the improved glucose tolerance under pioglitazone treatment in the obese Zucker fa/fa rat.
Adipose tissue differentiation is present only in the soleus muscle. We have then measured the expression of two genes (FAS and PEPCK) involved in lipid storage which are only expressed in mature adipocytes and not in muscles. In epitrochlearis and EDL muscles, FAS and PEPCK mRNAs were not detected in rats treated or not with pioglitazone, even after extensive exposures of the blots (results not shown). The presence of C/EBPa mRNA also could not be detected in these muscles (results not shown). In contrast, in the soleus muscle, FAS mRNA could be detected even in the control group, suggesting the presence of some adipose tissue in this oxidative muscle. Moreover, after the pioglitazone treatment, there was a clear-cut increase in FAS, PEPCK and C/ EBPa mRNAs (Fig. 2) , indicating the existence of an adipose tissue differentiation in the soleus.
In in vitro experiments, TZD, when inducing the conversion of myoblasts into adipocyte-like cells, strongly decreased the expression of myogenin, a transcription factor involved in the execution of the myogenic differentiation programme. If there was an important conversion of myoblasts into adipose tissue in the soleus muscle, then a decreased expression of myogenin could be anticipated. The expression of this gene was not affected by the pioglitazone treatment in the soleus (Fig. 3) or in the epitrochlearis muscles (data not shown).
Discussion
As previously described in humans and animal models of insulin resistance, pioglitazone is able to improve insulin sensitivity of glucose-utilizing tissues Fig. 1 . Effect of pioglitazone treatment on glucose utilization in the soleus, epitrochlearis and EDL muscles in the basal state and during a euglycaemic hyperinsulinaemic clamp in the obese Zucker fa/fa rat. Data are expressed as means ± SEM with eight animals in each experimental group. *p < 0.05, **p < 0.01, ***p < 0.001 for pioglitazone-treated vs control; ##p < 0.01, ###p < 0.001 for clamp vs basal state markedly. In the post-absorptive state, we have shown previously in obese Zucker fa/fa rats that adipose tissue is the main tissue increasing its glucose utilization under TZD treatment [12] . In contrast, during insulin stimulation, we show that muscles play also an important role in the increased glucose turnover rate. This can be explained by the difference in insulin sensitivity of these two tissues, with adipose tissue being more sensitive to the hormone than muscles [20] . Here we show that under insulin stimulation muscle fibre composition does not markedly affect the TZD-induced increase of glucose utilization in a highly insulin-resistant animal model. This suggests that oxidative muscle metabolism is not the primary target of TZD action. This is reminiscent of what was observed in rats in which a moderate insulin resistance was induced by fat feeding and treated with ciglitazone [21] .
The only well described mechanism of TZD action is linked to their binding and subsequent activation of PPARg leading to adipocyte differentiation both in vivo and in vitro. The physiological importance of PPARg in muscles is controversial. In rodents a very small expression of this factor was found in muscles [22] . In human muscles, the expression of PPARg is also extremely small when compared with its expression in adipose tissue [23, 24] . However, even a small amount of PPARg seems to be sufficient to induce the conversion of mouse satellite muscle cells into adipocytes as shown by in vitro experiments [11] .
In the present in vivo study, we show clearly that no adipocyte markers could be detected before and after pioglitazone treatment in muscles which do not possess amounts of adipose tissue (EDL and epitrochlearis muscles) which were previously detectable and hence that a similar TZD-induced phenomenon does not exist in vivo. We cannot exclude that adipocyte accumulation may occur in these muscles for a longer TZD treatment. An adipose tissue differentiation is only detectable in the soleus, in which adipose tissue is present before TZD treatment. Only in soleus muscle could a TZD-increased glucose utilization be detected in the post-absorptive state. This could be due to the presence of an increased amount of highly insulin-sensitive adipose tissue. Finally, appearance of newly differentiated adipocytes in the soleus is not concomitant with a decreased expression of myogenin, a muscle specific transcription factor, as described previously in vitro [25] . Nevertheless, these experiments do not totally rule out the possibil- Fig. 2 . Effects of pioglitazone treatment on FAS, PEPCK, and C/EBPa expression in the soleus muscle as analysed by northern-blotting. Pioglitazone was given orally to 12-week-old female Zucker fa/fa rats for 28 days. Each lane represents a different animal (n = 7 for the Zucker fa/fa rats (fa/fa) and 9 for the pioglitazone-treated Zucker fa/fa rats (fa/fa + Pio)) Fig. 3 . Effects of pioglitazone treatment on myogenin mRNA in soleus muscle. Pioglitazone was given orally to 12-week-old female Zucker fa/fa rats for 28 days. Each lane represents a different animal (n = 7 for the Zucker fa/fa rats (fa/fa) and 9 for the pioglitazone-treated Zucker fa/fa rats (fa/fa + Pio)).The blot presented is the same as that used in Fig. 2 ity that the appearance of newly differentiated adipocytes in the soleus is linked to some myoblast transdifferentiation.
We concluded: (i) the conversion of myoblasts into adipocytes after a 4-week TZD treatment in vivo, if it exists, is a marginal phenomenon; (ii) the presence of PPARg mRNA in muscles must be interpretated cautiously due to the potential contamination by mature adipocytes or even preadipocytes if subsequent cultures are performed; (iii) an increased amount of adipose tissue in muscles cannot explain their increased insulin sensitivity for glucose utilization. Indeed, although this increase is similar in the three muscles studied, the soleus is the only one in which adipose tissue differentiation is present. Moreover, the amount of adipose tissue in the soleus after TZD treatment is probably modest since, for a similar amount of total RNA on Northern-blots, the appearance of a signal for FAS and PEPCK cDNA probes requires only 24 h of film exposure in white adipose tissue [12] but at least 1 week in the soleus muscle.
Agents of the thiazolidinedione family are potent insulin sensitizers used at present to improve insulin sensitivity in Type II diabetes mellitus. If their action is exclusively through PPARg, then (i) one possibility is that the small amount of PPARg in muscles [22] (see above) is sufficient to induce changes in gene expression favouring insulin action, (ii) if their action is restricted to adipose tissue, they could modulate the secretion of circulating insulin agonists or antagonists or both by adipose tissue. TNFa or leptin or both could then be obvious candidates although the existence of a still unknown factor cannot be excluded. TNFa has been implicated in the insulin resistance of obesity and Type II diabetes mellitus [26, 27] and TZD are able to normalize the overexpression of TNFa mRNA and prevent TNFa-induced insulin resistance [28, 29] . Leptin seems also to have an anti-insulin effect [30] and TZD are able to decrease leptin mRNA expression [12, 31] , (iii) finally, as described recently for leukotriene B4 [32] , TZD not only could bind to the nuclear receptor PPARg but also to a membrane receptor present in muscles, mediating the insulin sensitizing process. This later possibility is re-enforced by the recent demonstration that in a mouse model of genetically ablated adipose tissue, troglitazone can still improve the diabetic state [33] .
